Sanofi (EPA: SAN), a leading French pharmaceutical company, has entered into a strategic agreement with Orano Med, a subsidiary of the French Orano Group, to enhance the development of next-generation radioligand medicines. The collaboration aims to accelerate the growth of radioligand therapies (RLTs) based on lead-212 (212Pb) alpha-emitting isotopes, which show promise in targeted cancer treatments.
Under the terms of the agreement, Sanofi and Orano will jointly invest in a new entity that will operate under the Orano Med brand. This entity will focus on the discovery, design, and clinical development of innovative radioligand therapies. Sanofi’s commitment to the venture includes an equity investment of EUR 300 million, securing approximately a 16% equity stake in the new entity, which is valued at EUR 1.9 billion.
This move follows Sanofi’s entry into the radioligand medicine sector in September of this year, where the company signed a licensing deal worth EUR 320 million with Orano Med and RadioMedix. The agreement aimed to advance radioligand therapies for rare cancers, with a particular focus on a late-stage project known as AlphaMedix.
The collaboration between Sanofi and Orano Med underscores the growing interest in radioligand therapies as a potential new frontier in cancer treatment, highlighting Sanofi’s strategic expansion into this innovative field.- Flcube.com
